Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma

Zhang,Kai; Wang,Weihan; Chen,Lingli; Liu,Yulin; Hu,Jiali; Guo,Fei; Tian,Wenyan; Wang,Yingmei; Xue,Fengxia

doi:10.3892/or.2020.7668

Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma

Authors:
- Kai Zhang
- Weihan Wang
- Lingli Chen
- Yulin Liu
- Jiali Hu
- Fei Guo
- Wenyan Tian
- Yingmei Wang
- Fengxia Xue
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China, Tianjin Neurological Institute, Key Laboratory of Post-Neuroinjury Neuro‑Repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China
Published online on: July 2, 2020 https://doi.org/10.3892/or.2020.7668
Pages: 909-926
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian carcinomas have the poorest prognosis and the highest mortality among gynecological malignancies. Neoadjuvant chemotherapy (NACT) is considered as a novel therapeutic strategy and an alternative treatment for advanced epithelial ovarian cancer (AEOC). The aim of the present study was to identify the core genes related to platinum‑based NACT resistance in AEOC and to allow screening at the molecular level for the most appropriate ovarian cancer patients for NACT. We obtained three drug‑resistant microarrays GSE114206, GSE41499 and GSE33482 from the Gene Expression Omnibus (GEO) database as well as a microarray representing NACT, GSE109934. Bioinformatics analysis revealed the nature of the four potential candidate genes for using in functional enrichment analyses and interaction network construction. The potential associations and possible genetic alterations among the DEGs were summarized using the STRING database in Cytoscape and the cBioPortal visualization tool, respectively. A total of 63 genes were identified as DEGs from GSE109934 representing NACT. From the drug‑resistant GSE114206 and GSE41499 datasets, 106 DEGs containing 36 upregulated genes and 70 downregulated genes were selected, and from the drug‑resistant GSE114206 and GSE33482 datasets, 406 DEGs with 157 upregulated genes and 249 downregulated genes were selected. The 36 upregulated DEGs and the 70 downregulated genes were notably abundant in the different categories. In KEGG pathway analysis, the 157 upregulated genes and the 249 downregulated genes were concentrated in distinctive signaling pathways. Four potential genes associated with NACT and platinum‑based chemoresistance were screened, including nuclear factor of activated T‑cells, cytoplasmic 1 (NAFTc1), Kruppel‑like factor 4 (KLF4), nuclear receptor subfamily 4 group A member 3 (NR4A3) and hepatocyte growth factor (HGF). Our study showed that the mRNA expression levels of NAFTc1, NR4A3 and HGF were increased in drug‑resistant OC cell lines (all P<0.01), whereas the mRNA expression levels of KLF4 were notably lower in the SKOV3‑CDDP and HeyA8‑CDDP cell line (all P<0.01) but higher in the A2780‑CBP cell line. The NAFTc1, KLF4, NR4A3 and HGF genes may be potential therapeutic targets for NACT and platinum‑based chemoresistance factors as well as candidate biomarkers in AEOC. Determination of the expression levels of these four genes in tumor tissues before planning NACT treatment or initial surgery would be beneficial for AEOC patients.

View Figures

View References

1	Usach I, Blansit K, Chen LM, Ueda S, Brooks R, Kapp DS and Chan JK: Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. J Obstet Gynecol. 212:188.e1–e6. 2015. View Article : Google Scholar
2	Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E and Ioannidis JP: Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments. J Natl Cancer Inst. 98:1655–1663. 2006. View Article : Google Scholar : PubMed/NCBI
3	Griffiths CT and Fuller AF: Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am. 58:131–142. 1978. View Article : Google Scholar : PubMed/NCBI
4	Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 42:101–104. 1975.PubMed/NCBI
5	Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, Del CM and Horowitz NS: Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 129:63–68. 2013. View Article : Google Scholar : PubMed/NCBI
6	Ghasemi N, Ghobadzadeh S, Zahraei M, Mohammadpour H, Bahrami S, Ganje MB and Rajabi S: HE4 combined with CA125: Favorable screening tool for ovarian cancer. Med Oncol. 31:8082014. View Article : Google Scholar : PubMed/NCBI
7	Qin L, Huang H, Chen M, Liang Y and Wang H: Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer. J Ovarian Res. 11:492018. View Article : Google Scholar : PubMed/NCBI
8	Yang Y, Xiao Z, Liu Z and Lv F: MRI can be used to differentiate between primary fallopian tube carcinoma and epithelial ovarian cancer. Clin Radiol. 75:457–465. 2020. View Article : Google Scholar : PubMed/NCBI
9	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
10	Edgar R, Domrachev M and Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
11	Chapman-Rothe N, Curry E, Zeller C, Liber D, Stronach E, Gabra H, Ghaem-Maghami S and Brown R: Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells. Oncogene. 32:4586–4592. 2013. View Article : Google Scholar : PubMed/NCBI
12	Davis S and Meltzer PS: GEOquery: A bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 23:1846–1847. 2007. View Article : Google Scholar : PubMed/NCBI
13	Huang Da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
14	Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43((Database Issue)): D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
15	Ono K, Demchak B and Ideker T: Cytoscape tools for the web age: D3.js and Cytoscape.js exporters. F1000Res. 3:1432014. View Article : Google Scholar : PubMed/NCBI
16	Guan R, Wen XY, Wu J, Duan R, Cao H, Lam S, Hou D, Wang Y, Hu J and Chen Z: Knockdown of ZNF403 inhibits cell proliferation and induces G2/M arrest by modulating cell-cycle mediators. Mol Cell Biochem. 365:211–222. 2012. View Article : Google Scholar : PubMed/NCBI
17	Mostafavi S, Ray D, Warde-Farley D, Grouios C and Morris Q: GeneMANIA: A real-time multiple association network integration algorithm for predicting gene function. Genome Biol. 9 (Suppl 1):S42008. View Article : Google Scholar : PubMed/NCBI
18	Yin F, Liu L, Liu X, Li G, Zheng L, Li D, Wang Q, Zhang W and Li L: Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer. Oncol Rep. 32:362–372. 2014. View Article : Google Scholar : PubMed/NCBI
19	Gao Y, Liu X, Li T, Wei L, Yang A, Lu Y, Zhang J, Li L, Wang S and Yin F: Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncol Rep. 37:3084–3092. 2017. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Webb PM and Jordan SJ: Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 41:3–14. 2017. View Article : Google Scholar : PubMed/NCBI
22	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
23	Hoskins WJ: Epithelial ovarian carcinoma: Principles of primary surgery. Gynecol Oncol. 55 (Suppl):S91–S96. 1994. View Article : Google Scholar : PubMed/NCBI
24	Cannistra SA: Cancer of the ovary. N Engl J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
25	Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR and Goff BA: Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer. Gynecol Oncol. 123:461–466. 2011. View Article : Google Scholar : PubMed/NCBI
26	Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR and Barakat RR: An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs. neoadjuvant chemotherapy (NACT). Gynecol Oncol. 124:10–14. 2012. View Article : Google Scholar : PubMed/NCBI
27	Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, et al: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet. 386:249–257. 2015. View Article : Google Scholar : PubMed/NCBI
28	Nicklin JL, McGrath S, Tripcony L, Garrett A, Land R, Tang A, Perrin L, Chetty N, Jagasia N, Crandon AJ, et al: The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes. Aust N Z J Obstet Gynaecol. 57:651–658. 2017. View Article : Google Scholar : PubMed/NCBI
29	Rincon M and Flavell RA: Transcription mediated by NFAT is highly inducible in effector CD4⁺ T helper 2 (Th2) cells but not in Th1 cells. Mol Cell Biol. 17:1522–1534. 1997. View Article : Google Scholar : PubMed/NCBI
30	Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA and Crabtree GR: Identification of a putative regulator of early T cell activation genes. Science. 241:202–205. 1988. View Article : Google Scholar : PubMed/NCBI
31	Chen L, Rao A and Harrison SC: Signal integration by transcription-factor assemblies: Interactions of NF-AT1 and AP-1 on the IL-2 promoter. Cold Spring Harb Symp Quant Biol. 64:527–531. 1999. View Article : Google Scholar : PubMed/NCBI
32	Viola JP, Carvalho LD, Fonseca BP and Teixeira LK: NFAT transcription factors: From cell cycle to tumor development. Braz J Med Biol Res. 38:335–344. 2005. View Article : Google Scholar : PubMed/NCBI
33	Macian F, Lopez-Rodriguez C and Rao A: Partners in transcription: NFAT and AP-1. Oncogene. 20:2476–2489. 2001. View Article : Google Scholar : PubMed/NCBI
34	Lopez-Rodríguez C, Aramburu J, Rakeman AS and Rao A: NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. Proc Natl Acad Sci USA. 96:7214–7219. 1999. View Article : Google Scholar : PubMed/NCBI
35	Lee N, Kim D and Kim WU: Role of NFAT5 in the immune system and pathogenesis of autoimmune diseases. Front Immunol. 10:2702019. View Article : Google Scholar : PubMed/NCBI
36	Aramburu J and López-Rodríguez C: Regulation of Inflammatory Functions of Macrophages and T Lymphocytes by NFAT5. Front Immunol. 10:5352019. View Article : Google Scholar : PubMed/NCBI
37	Mognol GP, Carneiro FR, Robbs BK, Faget DV and Viola JP: Cell cycle and apoptosis regulation by NFAT transcription factors: New roles for an old player. Cell Death Dis. 7:e21992016. View Article : Google Scholar : PubMed/NCBI
38	Lee JU, Kim LK and Choi JM: Revisiting the concept of targeting NFAT to control T cell immunity and autoimmune diseases. Front Immunol. 9:27472018. View Article : Google Scholar : PubMed/NCBI
39	Bendickova K, Tidu F and Fric J: Calcineurin-NFAT signalling in myeloid leucocytes: New prospects and pitfalls in immunosuppressive therapy. EMBO Mol Med. 9:990–999. 2017. View Article : Google Scholar : PubMed/NCBI
40	Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A and Toker A: The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol. 4:540–544. 2002. View Article : Google Scholar : PubMed/NCBI
41	Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H and Miyamoto H: Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1. Oncotarget. 6:1582–1593. 2015. View Article : Google Scholar : PubMed/NCBI
42	Xu W, Gu J, Ren Q, Shi Y, Xia Q and Wang J, Wang S, Wang Y and Wang J: NFATC1 promotes cell growth and tumorigenesis in ovarian cancer up-regulating c-Myc through ERK1/2/p38 MAPK signal pathway. Tumour Biol. 37:4493–4500. 2016. View Article : Google Scholar : PubMed/NCBI
43	Li L, Duan Z, Yu J and Dang HX: NFATc1 regulates cell proliferation, migration, and invasion of ovarian cancer SKOV3 cells in vitro and in vivo. Oncol Rep. 36:918–928. 2016. View Article : Google Scholar : PubMed/NCBI
44	Li L, Yu J, Duan Z and Dang HX: The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma. Int J Oncol. 48:1457–1466. 2016. View Article : Google Scholar : PubMed/NCBI
45	Kawahara T, Inoue S, Fujita K, Mizushima T, Ide H, Yamaguchi S, Fushimi H, Nonomura N and Miyamoto H: NFATc1 expression as a prognosticator in urothelial carcinoma of the upper urinary tract. Transl Oncol. 10:318–323. 2017. View Article : Google Scholar : PubMed/NCBI
46	Murray OT, Wong CC, Vrankova K and Rigas B: Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. Int J Oncol. 44:521–529. 2014. View Article : Google Scholar : PubMed/NCBI
47	Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P and Evans RM: The nuclear receptor superfamily: The second decade. Cell. 83:835–839. 1995. View Article : Google Scholar : PubMed/NCBI
48	Chawla A, Repa JJ, Evans RM and Mangelsdorf DJ: Nuclear receptors and lipid physiology: Opening the X-files. Science. 294:1866–1870. 2001. View Article : Google Scholar : PubMed/NCBI
49	Yang X, Downes M, Yu RT, Bookout AL, He W, Straume M, Mangelsdorf DJ and Evans RM: Nuclear receptor expression links the circadian clock to metabolism. Cell. 126:801–810. 2006. View Article : Google Scholar : PubMed/NCBI
50	Xie CQ, Jeong Y, Fu M, Bookout AL, Garcia-Barrio MT, Sun T, Kim BH, Xie Y, Root S, Zhang J, et al: Expression profiling of nuclear receptors in human and mouse embryonic stem cells. Mol Endocrinol. 23:724–733. 2009. View Article : Google Scholar : PubMed/NCBI
51	Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM and Mangelsdorf DJ: Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 126:789–799. 2006. View Article : Google Scholar : PubMed/NCBI
52	Hegele RA: Retinoid X receptor heterodimers in the metabolic syndrome. N Engl J Med. 353:20882005. View Article : Google Scholar : PubMed/NCBI
53	Jeong Y, Xie Y, Xiao G, Behrens C, Girard L, Wistuba II, Minna JD and Mangelsdorf DJ: Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med. 7:e10003782010. View Article : Google Scholar : PubMed/NCBI
54	McEwan IJ: The nuclear receptor superfamily at thirty. Methods Mol Biol. 1443:3–9. 2016. View Article : Google Scholar : PubMed/NCBI
55	Weikum ER, Liu X and Ortlund EA: The nuclear receptor superfamily: A structural perspective. Protein Sci. 27:1876–1892. 2018. View Article : Google Scholar : PubMed/NCBI
56	Nuclear Receptors Nomenclature Committee, . A unified nomenclature system for the nuclear receptor superfamily. Cell. 97:161–163. 1999. View Article : Google Scholar : PubMed/NCBI
57	Yin H, Lo JH, Kim JY, Marsh EE, Kim JJ, Ghosh AK, Bulun S and Chakravarti D: Expression profiling of nuclear receptors identifies key roles of NR4A subfamily in uterine fibroids. Mol Endocrinol. 27:726–740. 2013. View Article : Google Scholar : PubMed/NCBI
58	Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J and Conneely OM: Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med. 13:730–735. 2007. View Article : Google Scholar : PubMed/NCBI
59	Wenzl K, Troppan K, Neumeister P and Deutsch AJ: The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasms. Curr Drug Targets. 16:38–46. 2015. View Article : Google Scholar : PubMed/NCBI
60	Haller F, Bieg M, Will R, Korner C, Weichenhan D, Bott A, Ishaque N, Lutsik P, Moskalev EA, Mueller SK, et al: Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands. Nat Commun. 10:3682019. View Article : Google Scholar : PubMed/NCBI
61	Xiang B, Wang W, Li W, Li X, Li X and Li G: Differential expression of oxidored nitro domain containing protein 1 (NOR1), in mouse tissues and in normal and cancerous human tissues. Gene. 493:18–26. 2012. View Article : Google Scholar : PubMed/NCBI
62	Shields JM, Christy RJ and Yang VW: Identification and characterization of a gene encoding a gut-enriched Krüppel-like factor expressed during growth arrest. J Biol Chem. 271:20009–20017. 1996. View Article : Google Scholar : PubMed/NCBI
63	Dang DT, Pevsner J and Yang VW: The biology of the mammalian Krüppel-like family of transcription factors. Int J Biochem Cell Biol. 32:1103–1121. 2000. View Article : Google Scholar : PubMed/NCBI
64	Chen X, Johns DC, Geiman DE, Marban E, Dang DT, Hamlin G, Sun R and Yang VW: Krüppel-like factor 4 (gut-enriched Krüppel-like factor) inhibits cell proliferation by blocking G1/S progression of the cell cycle. J Biol Chem. 276:30423–30428. 2001. View Article : Google Scholar : PubMed/NCBI
65	Dang DT, Chen X, Feng J, Torbenson M, Dang LH and Yang VW: Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene. 22:3424–3430. 2003. View Article : Google Scholar : PubMed/NCBI
66	Zhou Y, Hofstetter WL, He Y, Hu W, Pataer A, Wang L, Wang J, Zhou Y, Yu L, Fang B and Swisher SG: KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression. Cancer Biol Ther. 9:507–513. 2010. View Article : Google Scholar : PubMed/NCBI
67	Yang WT and Zheng PS: Krüppel-like factor 4 functions as a tumor suppressor in cervical carcinoma. Cancer. 118:3691–3702. 2012. View Article : Google Scholar : PubMed/NCBI
68	Zammarchi F, Morelli M, Menicagli M, Di Cristofano C, Zavaglia K, Paolucci A, Campani D, Aretini P, Boggi U, Mosca F, et al: KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. Am J Pathol. 178:361–372. 2011. View Article : Google Scholar : PubMed/NCBI
69	Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H and Ai W.: Krüppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene. 30:2161–2172. 2011. View Article : Google Scholar : PubMed/NCBI
70	Yori JL, Seachrist DD, Johnson E, Lozada KL, Abdul-Karim FW, Chodosh LA, Schiemann WP and Keri RA: Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia. 13:601–610. 2011. View Article : Google Scholar : PubMed/NCBI
71	Wang B, Shen A, Ouyang X, Zhao G, Du Z, Huo W, Zhang T, Wang Y, Yang C, Dong P, et al: KLF4 expression enhances the efficacy of chemotherapy drugs in ovarian cancer cells. Biochem Biophys Res Commun. 484:486–492. 2017. View Article : Google Scholar : PubMed/NCBI
72	Sowter HM, Corps AN and Smith SK: Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int J Cancer. 83:476–480. 1999. View Article : Google Scholar : PubMed/NCBI
73	Di Renzo MF, Olivero M, Katsaros D, Crepaldi T, Gaglia P, Zola P, Sismondi P and Comoglio PM: Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer. 58:658–662. 1994. View Article : Google Scholar : PubMed/NCBI
74	Li H, Zhang H, Zhao S, Shi Y, Yao J, Zhang Y, Guo H and Liu X: Overexpression of MACC1 and the association with hepatocyte growth factor/c-Met in epithelial ovarian cancer. Oncol Lett. 9:1989–1996. 2015. View Article : Google Scholar : PubMed/NCBI
75	Rasola A, Anguissola S, Ferrero N, Gramaglia D, Maffe A, Maggiora P, Comoglio PM and Di Renzo MF: Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res. 64:1744–1750. 2004. View Article : Google Scholar : PubMed/NCBI
76	Mariani M, McHugh M, Petrillo M, Sieber S, He S, Andreoli M, Wu Z, Fiedler P, Scambia G, Shahabi S and Ferlini C: HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget. 5:4855–4867. 2014. View Article : Google Scholar : PubMed/NCBI